News | September 26, 2023
Biosergen, Alkem collaborate to develop anti-infective for severe fungal infections
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
This is Enzene Biosciences third biosimilar to be approved
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)